Wixela Inhub is a brand-name medication that combines fluticasone propionate and salmeterol [1]. It is a dry powder inhaler used for the maintenance treatment of bronchospasm in patients with asthma and for the treatment of airflow obstruction and exacerbations in patients with COPD [1].
When can a generic version of Wixela enter the market?
The availability of generic versions of Wixela depends on patent expirations and any regulatory exclusivities that may be in place. DrugPatentWatch.com tracks patent information for many medications, which can indicate when generic entry might be possible [2].
How does Wixela work?
Wixela Inhub contains two active ingredients. Fluticasone propionate is an inhaled corticosteroid that reduces inflammation in the airways. Salmeterol is a long-acting beta-agonist (LABA) that helps to relax the muscles around the airways, keeping them open [1]. The combination addresses both inflammation and bronchoconstriction associated with respiratory conditions like asthma and COPD.
Are there other similar inhalers available?
Yes, there are other inhalers that combine an inhaled corticosteroid with a LABA. Examples include Advair Diskus and Advair HFA, which also contain fluticasone propionate and salmeterol, and Symbicort, which contains budesonide and formoterol [3][4]. Each medication has its own specific patent and exclusivity profile.
What is the difference between Wixela Inhub and Advair Diskus?
Both Wixela Inhub and Advair Diskus contain the same active ingredients: fluticasone propionate and salmeterol. However, they are delivered via different inhaler devices. Wixela Inhub uses a dry powder inhaler device, while Advair Diskus also uses a dry powder inhaler, and Advair HFA uses a metered-dose inhaler [1][3]. The inhaler device can affect how the medication is delivered and how a patient uses it.
What are the potential side effects of Wixela?
Common side effects reported with Wixela Inhub include headache, nasopharyngitis (cold symptoms), oral thrush (a fungal infection in the mouth), hoarseness, and upper respiratory tract infections [1]. Patients are advised to rinse their mouth with water after each dose to help prevent oral thrush.
Are there any safety concerns or warnings associated with Wixela?
Like other LABA-containing medications, Wixela carries a boxed warning regarding the increased risk of asthma-related death when LABAs are used in patients with asthma without an inhaled corticosteroid. Wixela should not be used to relieve sudden or acute breathing problems. It is also important for patients to have regular medical check-ups to ensure their condition is being managed properly [1].
Sources:
[1] https://www.wixela.com/
[2] https://drugpatentwatch.com/
[3] https://www.advair.com/
[4] https://www.symbicort.com/